Aptose ex-director disposes all shares in Hammi deal
Rhea-AI Filing Summary
Aptose Biosciences Inc. former director Denis R. Burger reported the disposition of his remaining stake in connection with the company’s acquisition by Hammi Pharmaceuticals Co. Ltd.
On June 30, 2026, he disposed of 70 Common Shares at $1.72 per share, reflecting a Canadian purchase price of C$2.41 converted using an exchange rate of C$1.4 = US$1.00.
Burger also disposed of multiple stock option grants, including director stock options with exercise prices such as $1.14, $2.80, and $6.91 per share, with expirations running through 2034. After these issuer-directed dispositions, his reported holdings of Aptose common shares and related options were zero.
Positive
- None.
Negative
- None.
Insider Trade Summary
Disposition: 528,737 shares
Disposition
11 txns
Insider
BURGER DENIS R
Role
Insider
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Director Stock Option (Right to Buy) | 3,333 | $0.00 | $0.00 |
| Disposition | Director Stock Option (Right to Buy) | 100,000 | $0.00 | $0.00 |
| Disposition | Director Stock Option (Right to Buy) | 50,000 | $0.00 | $0.00 |
| Disposition | Director Stock Option (Right to Buy) | 50,000 | $0.00 | $0.00 |
| Disposition | Director Stock Option (Right to Buy) | 50,000 | $0.00 | $0.00 |
| Disposition | Director Stock Option (Right to Buy) | 160,334 | $0.00 | $0.00 |
| Disposition | Stock Options (Right to Buy) | 40,000 | $0.00 | $0.00 |
| Disposition | Director Stock Option (Right to Buy) | 5,000 | $0.00 | $0.00 |
| Disposition | Director Stock Option (Right to Buy) | 60,000 | $0.00 | $0.00 |
| Disposition | Director Stock Option (Right to Buy) | 10,000 | $0.00 | $0.00 |
| Disposition | Common Shares | 70 | $1.72 | $120.40 |
Holdings After Transaction:
Director Stock Option (Right to Buy) — 0 contracts (Direct);
Stock Options (Right to Buy) — 0 contracts (Direct);
Common Shares — 0 shares (Direct)
Footnotes (3)
- F1. Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share.
- F2. Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00.
- F3. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date.
Key Figures
Common Shares disposed: 70 shares
Share price (U.S.): $1.72 per share
Acquisition price: C$2.41 per share
+5 more
8 metrics
Common Shares disposed
70 shares
Common Shares transferred on June 30, 2026
Share price (U.S.)
$1.72 per share
Converted from C$2.41 using C$1.4 = US$1.00
Acquisition price
C$2.41 per share
Hammi subsidiary acquisition of all outstanding Aptose shares
Option exercise price
$1.14 per share
Director Stock Option disposed, expires March 28, 2027
Option exercise price
$2.80 per share
Director Stock Option disposed, expires January 19, 2028
Largest option block
160,334 options
Director Stock Option at $6.91, expires January 30, 2030
Post-transaction holdings
0 shares/options
Total shares following transaction reported as zero
Exchange rate used
C$1.4 = US$1.00
Conversion of C$2.41 acquisition price for Form 4 reporting
Key Terms
Disposition to issuer, Director Stock Option (Right to Buy), business arrangement agreement, acquired all outstanding shares, +2 more
6 terms
Disposition to issuer financial
"transaction_code_description: Disposition to issuer"
Director Stock Option (Right to Buy) financial
"security_title: Director Stock Option (Right to Buy)"
business arrangement agreement regulatory
"business arrangement agreement between the Issuer and Hammi Pharmaceuticals"
exchange rate financial
"using an exchange rate of C$1.4 = US$1.00"
Exchange rate is the price of one currency expressed in another—for example, how many euros you receive for one US dollar. It matters to investors because changes in that price alter the reported profits, costs and value of assets for companies and portfolios that operate or hold money across borders; think of it like switching measurement units, where the same item can look bigger or smaller depending on the unit used.
Options vest 50% on first anniversary financial
"Options vest 50% on first anniversary of grant date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Denis R. Burger report in this Aptose Biosciences (APTOF) Form 4?
Denis R. Burger reported disposing of all his Aptose holdings. He transferred 70 Common Shares and multiple stock option grants back to the issuer on June 30, 2026, leaving him with zero reported Aptose shares or options after the transaction.
What types of Aptose (APTOF) derivatives did Denis R. Burger dispose of?
He disposed of several director stock option awards and stock options, each giving rights to buy Common Shares. These options had exercise prices ranging from $0.66 to $6.91 per share and expiration dates extending from 2027 through 2034, all reported with zero remaining holdings.
Did Denis R. Burger retain any Aptose Biosciences (APTOF) holdings after this Form 4?
No. The Form 4 shows total shares following each transaction as zero. After disposing of 70 Common Shares and all listed stock option positions, the filing reports no remaining Aptose common shares or related options held by Denis R. Burger.
AI-generated analysis. How Rhea-AI works. Not financial advice.
